Skip to main content

Table 3 GRADE evidence profile of RCTs for effect of BPs on periprosthetic bone loss after TKA

From: Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials

  Summary of findings Quality assessment
Time points n (treated/control) WMD (95%CI, g/cm2) Limitations Inconsistency Indirectness Imprecision Others Quality
Tibia 3 months 2 (48/50) 0.07 (0.04–0.10) No seriousa No seriousb No serious Seriousc Strong associationd Moderate
6 months 3 (78/80) 0.12 (0.10–0.15) No serious No serious No serious No serious Strong associationd High
12 months 3 (77/75) 0.12 (0.10–0.15) No serious Serious No serious No serious None Moderate
Femur 3 months 3 (56/61) 0.07 (0.04–0.10) No serious No serious No serious Serious Strong association Moderate
6 months 5 (91/97) 0.12 (0.10–0.15) No serious Serious No serious No serious Strong association Moderate
12 months 4 (85/86) 0.12 (0.10–0.15) No serious Serious No serious No serious Strong association Moderate
  1. aThe inadequate blinding and substantial loss follow-up in some trials may raise risk of bias
  2. bInconsistent report of outcomes and significant heterogeneity existed across the trials
  3. cThe number of included patients less than 150 is considered to be small and may cause imprecision
  4. dEffect size more than 0.05 is considered to be large and strengthen the evidence